Treatment of triple receptor negative breast cancer

Abstract

The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer.

The invention claimed is:  
     
       1. A method of treating breast cancer comprising administering a therapeutically effective amount of a combination of formulations to a human patient, wherein the formulations include
 (a) a formulation comprising a cationic liposomal preparation comprising at least one cationic lipid from about 30 mole % to about 99.9 mole %, a taxane in an amount of at least about 0.1 mole %, and at least one neutral lipid from about 30 mole % to about 70 mole %, wherein the liposomal preparation has a zeta potential in the range of about 0 mV to about 100 mV in about 0.05 mM KCl solution at about pH 7.5; and 
 (b) a formulation comprising a non-liposomal preparation comprising a taxane; and wherein the formulation comprising the cationic liposomal preparation is administered in a single dose of between about 1 mg/m 2  and about 50 mg/m 2  of taxane and the formulation comprising the non-liposomal taxane is administered in a single dose of between about 20 mg/m 2  and about 100 mg/m 2  of taxane. 
 
     
     
       2. The method of  claim 1 , wherein the liposomal preparation has a zeta potential in the range of about 20 mV to about 100 mV in about 0.05 mM KCl solution at about pH 7.5. 
     
     
       3. The method of  claim 1 , wherein the taxane is paclitaxel or a derivative thereof. 
     
     
       4. The method of  claim 3 , wherein the cationic liposomal preparation comprises paclitaxel in an amount of at least about 2 mole % to about 8 mole % or at least about 2.5 mole % to about 3.5 mole %. 
     
     
       5. The method of  claim 1 , wherein the cationic lipid is selected from the group consisting of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium salt (DOTAP); dimethyldioctadecyl ammonium bromide (DDAB); 1,2-diacyloxy-3-trimethylammonium propane N-[1-(2,3-dioloyloxy)propyl]-N,N-dimethyl amine (DODAP); 1,2-diacyloxy-3-dimethylammonium propane; N-[1-(2,3-dioleyloxyl)propyl]-N,N,N-trimethylammonium chloride (DOTMA); 1,2-dialkyloxy-3-dimethylammonium propane; dioctadecylamidoglycylspermine (DOGS); 3β-[N—(N′,N′-dimethylamino-ethane)carbamoyl]cholesterol (DC-Chol); 2,3-dioleoyloxy-N-(2-(sperminecarboxamido)-ethyl)-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA); β-alanyl cholesterol; cetyl trimethyl ammonium bromide (CTAB); diC14-amidine; N-tert-butyl-N′-tetradecyl-3-tetradecylamino-propionamidine; 14Dea2; N-(alpha-trimethylammonioacetyl)didodecyl-D-glutamate chloride (TMAG): O,O′-ditetradecanoyl-N-(trimethylammonioacetyl)diethanolamine chloride; 1,3-dioleoyloxy 2-(6-carboxy-spermyl)-propylamide (DOSPER); N,N,N′,N′-tetramethyl-N,N′-bis(2-hydroxylethyl)-2,3-dioleoyloxy-1,4-butanediammonium iodide; 1-[2-(acyloxy)ethyl]2-alkyl (alkenyl)-3-(2-hydroxyethyl)-imidazolinium chloride; 1,2-dioleoyl-3-dimethyl-hydroxyethyl ammonium bromide (DORI); 1,2-dioleyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE); 1,2-dioleyloxypropyl-3-dimethyl-hydroxypropyl ammonium bromide (DORIE-HP); 1,2-dioleyloxypropyl-3-dimethyl-hydroxybutyl ammonium bromide (DORIE-HB); 1,2-dioleyloxypropyl-3-dimethyl-hydroxypentyl ammonium bromide (DORIE-Hpe); 1,2-dimyristyloxypropyl-3-dimethyl-hydroxylethyl ammonium bromide (DMRIE); 1,2-dipalmityloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DPRIE); 1,2-disteryloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DSRIE); and 1,2-diacyl-sn-glycerol-3-ethylphosphocholine. 
     
     
       6. The method of  claim 1 , wherein the neutral lipid is selected from the group consisting of cholesterol; phospholipid; sphingolipid; and pegylated lipid with a neutral charge. 
     
     
       7. The method of  claim 1 , wherein the cationic liposomal preparation comprises DOTAP, DOPC, and paclitaxel. 
     
     
       8. The method of  claim 7 , wherein the cationic liposomal preparation comprises DOTAP, DOPC, and paclitaxel in a ratio of about 50:47:3. 
     
     
       9. The method of  claim 1 , wherein the formulations are administered sequentially. 
     
     
       10. The method of  claim 1 , wherein the formulations are administered simultaneously. 
     
     
       11. The method of  claim 1 , wherein the formulations are administered separately. 
     
     
       12. The method of  claim 1 , wherein the formulation comprising the cationic liposomal preparation and the formulation comprising the non-liposomal preparation are administered at different timepoints on the same day or on different days. 
     
     
       13. The method of  claim 1 , wherein the formulation comprising the cationic liposomal preparation is administered in a single dose of between about 20 mg/m 2  and about 50 mg/m 2  of taxane. 
     
     
       14. The method of  claim 13 , wherein the formulation comprising the cationic liposomal preparation is administered in a single dose of between about 20 mg/m 2  and about 40 mg/m 2  of taxane. 
     
     
       15. The method of  claim 14 , wherein the formulation comprising the cationic liposomal preparation is administered in a single dose of about 22 mg/m 2  of taxane. 
     
     
       16. The method of  claim 1 , wherein the formulation comprising the non-liposomal preparation is administered in a single dose of about 70 mg/m 2  of taxane. 
     
     
       17. The method of  claim 15 , wherein the formulation comprising the non-liposomal preparation is administered in a single dose of about 70 mg/m 2  of taxane. 
     
     
       18. The method of  claim 1 , wherein the formulation comprising the cationic liposomal preparation further comprises an anionic lipid in an amount of 30 mole % to 55 mole %. 
     
     
       19. The method of  claim 5 , wherein the 1-[2-(acyloxy)ethyl]2-alkyl (alkenyl)-3-(2-hydroxyethyl)-imidazolinium chloride is 1-[2-(9(Z)-octadecenoyloxy)ethyl]-2-(8(Z)-heptadecenyl-3-(2-hydroxyethyl)-imidazolinium chloride (DOTIM) or 1-[2-(hexadecanoyloxy)ethyl]-2-pentadecyl-3-(2-hydroxyethyl)imidazolinium chloride (DPTIM). 
     
     
       20. The method of  claim 1 , wherein the neutral lipid is selected from the group consisting of 1,2-diacyl-sn-glycero-3-phosphoethanolamine, 1,2-diacyl-sn-glycero-3-phosphocholine, and sphingomyelin. 
     
     
       21. The method of  claim 20 , wherein 1,2-diacyl-sn-glycero-3-phosphoethanolamine is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). 
     
     
       22. The method of  claim 20 , wherein 1,2-diacyl-sn-glycero-3-phosphocholine is 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 
     
     
       23. The method of  claim 6 , wherein the phospholipid is a lysophospholipid.